1. Home
  2. KRG vs TGTX Comparison

KRG vs TGTX Comparison

Compare KRG & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kite Realty Group Trust

KRG

Kite Realty Group Trust

HOLD

Current Price

$24.15

Market Cap

5.0B

Sector

Real Estate

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$31.76

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRG
TGTX
Founded
1971
1993
Country
United States
United States
Employees
228
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
4.9B
IPO Year
2004
2008

Fundamental Metrics

Financial Performance
Metric
KRG
TGTX
Price
$24.15
$31.76
Analyst Decision
Buy
Strong Buy
Analyst Count
11
5
Target Price
$25.82
$49.80
AVG Volume (30 Days)
1.5M
2.0M
Earning Date
04-28-2026
05-04-2026
Dividend Yield
4.78%
N/A
EPS Growth
6750.00
1746.67
EPS
1.37
2.77
Revenue
$844,365,000.00
$2,785,000.00
Revenue This Year
N/A
$49.30
Revenue Next Year
N/A
$24.55
P/E Ratio
$17.69
$11.53
Revenue Growth
0.30
N/A
52 Week Low
$18.52
$25.37
52 Week High
$26.38
$46.48

Technical Indicators

Market Signals
Indicator
KRG
TGTX
Relative Strength Index (RSI) 34.03 59.70
Support Level $21.87 $29.81
Resistance Level $24.50 $32.96
Average True Range (ATR) 0.47 1.40
MACD -0.21 0.31
Stochastic Oscillator 1.66 87.22

Price Performance

Historical Comparison
KRG
TGTX

About KRG Kite Realty Group Trust

Kite Realty Group Trust specializing in high-quality, open-air shopping centers and mixed-use assets. Concentrated in the Sun Belt and strategic gateway markets, the company focuses on grocery-anchored, necessity-based retail. The company generates the majority of its revenue from contractual rents and reimbursement payments received from tenants.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: